Pembrolizumab Shows Promise in Post-ASCT Hodgkin Lymphoma
Pembrolizumab improved PFS in this high-risk patient population, but a randomized controlled trial is warranted.
Hodgkin Lymphoma
Susceptibility to Radiation-Induced Breast Cancer Following Treatment for Hodgkin Lymphoma
Genetic variants associated with radiation-induced breast cancer include MYC-adjacent oncogene PVT1.
Postchemo Radiation Tx May Benefit Some With Hodgkin Lymphoma
For patients with advanced-stage Hodgkin lymphoma (HL) with large tumors, limited evidence suggests that consolidation radiotherapy (RT) after chemotherapy may prolong progression-free survival.
High 5-Year OS Rate for Children and Young Adults with Relapsed/Refractory Hodgkin Lymphoma Receiving Moderate-Dose Salvage RT
Results of a retrospective study of the treatment patterns and outcomes of a cohort of children and young adults with relapsed/refractory Hodgkin lymphoma showed high 5-year rates of freedom from local failure and overall survival (OS) in patients receiving moderate-dose salvage radiation therapy.
Consensus Panel on Maintenance Therapies Following Autologous Hematopoietic Cell Transplantation in Lymphoma
An expert panel reviewed current literature surrounding lymphoma treatment to identify and address any gaps in knowledge.
BMT Societies Issue Recommendations on Posttransplant Maintenance in HL/NHL
Use of maintenance therapy as a therapeutic strategy in posttransplant patients with HL and NHL is increasing in frequency
A 5-Feature Radiomics Model to Predict Refractory Disease in Early-Stage Hodgkin Lymphoma
A study of the use of precision medicine-based “radiomic” features to evaluate risk of refractory disease in early-stage Hodgkin lymphoma showed promising results.
Younger Women May Have Better Chance at Ovarian Function Recovery After Treatment for Hodgkin Lymphoma
Women aged 35 years or older diagnosed with Hodgkin lymphoma should discuss fertility preservation prior to treatment.
Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
Sequential dosing of brentuximab vedotin before and after standard doxorubicin, vinblastine, and dacarbazine showed a survival benefit in a phase II trial.
Checkpoint Inhibition for Non-Hodgkin and Hodgkin Lymphomas
Most non-Hodgkin lymphomas do not display the same genetic alteration as classical Hodgkin lymphoma, and are much less susceptible to PD-1 blockade.
-
Loading...
-
Loading...
